HKSE - Delayed Quote HKD

Keymed Biosciences Inc. (2162.HK)

47.500
-3.350
(-6.59%)
At close: June 13 at 4:08:07 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
428,124
428,124
354,095
100,063
110,269
Cost of Revenue
12,200
12,200
36,878
2,585
17,200
Gross Profit
415,924
415,924
317,217
97,478
93,069
Operating Expense
1,002,088
1,002,088
752,017
575,742
464,388
Operating Income
-586,164
-586,164
-434,800
-478,264
-371,319
Net Non Operating Interest Income Expense
69,869
69,869
71,087
45,919
-4,120
Pretax Income
-508,647
-508,647
-356,188
-303,597
-3,892,632
Tax Provision
6,260
6,260
1,597
0
0
Net Income Common Stockholders
-515,241
-515,241
-359,357
-308,115
-3,887,309
Diluted NI Available to Com Stockholders
-515,241
-515,241
-359,357
-308,115
-3,887,309
Basic EPS
-1.97
--
-1.37
-1.18
-24.17
Diluted EPS
-1.97
--
-1.37
-1.18
-24.17
Basic Average Shares
261,946.993
--
261,367.569
261,126.555
160,849.076
Diluted Average Shares
261,946.993
--
261,367.569
261,126.555
160,849.076
Rent Expense Supplemental
1,348
1,348
1,056
--
--
Total Expenses
1,014,288
1,014,288
788,895
578,327
481,588
Net Income from Continuing & Discontinued Operation
-515,241
-515,241
-359,357
-308,115
-3,887,309
Normalized Income
-515,287.500
-515,287.500
-359,357
-308,115
-3,887,309
Interest Income
88,329
88,329
88,346
54,316
7,013
Interest Expense
18,460
18,460
17,259
8,219
11,133
Net Interest Income
69,869
69,869
71,087
45,919
-4,120
EBIT
-490,187
-490,187
-338,929
-295,378
-3,881,499
EBITDA
-396,959
-396,959
-269,768
-259,255
-3,860,480
Reconciled Cost of Revenue
12,200
12,200
36,878
2,585
17,200
Reconciled Depreciation
93,228
93,228
69,161
36,123
21,019
Net Income from Continuing Operation Net Minority Interest
-515,241
-515,241
-359,357
-308,115
-3,887,309
Total Unusual Items Excluding Goodwill
62
62
0
--
0
Total Unusual Items
62
62
0
--
0
Normalized EBITDA
-397,021
-397,021
-269,768
-259,255
-3,860,480
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
15.500
15.500
0
0
0
12/31/2021 - 7/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

9966.HK Alphamab Oncology
8.000
-3.73%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
347.000
-4.51%
 
2171.HK CARsgen Therapeutics Holdings Limited
23.300
+0.22%
 
9995.HK RemeGen Co., Ltd.
53.550
-7.11%
 
2256.HK Abbisko Cayman Limited
10.240
0.00%
 
1167.HK JACOBIO-B
5.170
-6.34%
 
3681.HK SinoMab BioScience Limited
2.390
-10.15%
 
6821.HK Asymchem Laboratories (Tianjin) Co., Ltd.
79.050
-1.68%
 
2105.HK Laekna, Inc.
22.150
-3.28%
 
2157.HK Lepu Biopharma Co., Ltd.
5.920
-4.98%